ACI-35

ACI-35 is a first-generation, liposome-based active immunotherapy (vaccine) developed by AC Immune SA, in collaboration with Janssen Pharmaceuticals (now Johnson & Johnson Innovative Medicine), for the treatment of Alzheimer's disease. It consists of a tetra-palmitoylated phospho-tau (pTau) T3 peptide spanning residues 393-408 of the longest human Tau isoform, phosphorylated at pathological residues S396 and S404, embedded in a lipid bilayer along with the adjuvant monophosphoryl lipid A (MPLA). The vaccine contains 16 copies of this synthetic tau fragment. Its biological target is pathological phosphorylated tau (pTau) protein in the brain, and its mechanism is to elicit a specific antibody-mediated immune response against pathological conformers of pTau without triggering autoimmune responses against physiological tau. ACI-35 was evaluated in a Phase 1b clinical trial in patients with mild-to-moderate Alzheimer's disease, where it demonstrated a favorable safety and tolerability profile and an early target-specific antibody response against pTau, but failed to generate sustained antibody responses upon subsequent booster injections. It served as the basis for the second-generation vaccine ACI-35.030 (JNJ-64042056).

Other names

ACI-35ACI35ACI 35VAC20121VAC-20121VAC 20121